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There is increasing interest in the chronic lympho-
cytic leukemia (CLL) microenvironment and the
mechanisms that may promote CLL cell survival
and proliferation. A role for T helper (Th) cells has
been suggested, but current evidence is only circum-
stantial. Herewe show that CLL patients hadmemory
Th cells that were specific for endogenous CLL
antigens. These Th cells activated autologous CLL
cell proliferation in vitro and in human / mouse
xenograft experiments. Moreover, CLL cells were
efficient antigen-presenting cells that could endo-
cytose and process complex proteins through anti-
gen uptake pathways, including the B cell receptor.
Activation of CLL cells by Th cells was contact and
CD40L dependent. The results suggest that CLL is
driven by ongoing immune responses related to Th
cell–CLL cell interaction. We propose that Th cells
support malignant B cells and that they could be
targeted in the treatment of CLL.INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy
characterized by the accumulation of mature clonal CD5+ B cells
derived from proliferation within localized pseudofollicles in the
bone marrow and secondary lymphoid organs (Burger et al.,
2009). Studies show that the stromal microenvironment can
play a role in supporting CLL cell survival via antiapoptotic ef-
fects. CLL cells are thought to interact with the endothelia,
stroma, and monocyte-derived nurse-like cells in a process
involving cytokines as well as chemokines (Burger et al., 2009).
However, it remains to be demonstrated which specific cellular
andmolecularmechanisms support the proliferation ofCLL cells.
The B cell receptor (BCR) of B cells delivers a low-level, tonic
signal in the absence of antigen. CLL cells may express poly-566 Cell Reports 4, 566–577, August 15, 2013 ª2013 The Authorsreactive/crossreactive/autoreactive BCR that can support a
level of BCR signaling above this tonic signaling (Stevenson
et al., 2011; Du¨hren-von Minden et al., 2012). Moreover, a sub-
group of patients with mutated immunoglobulin H (IgH) chain (of
the VH7-3 family) have CLL cells with specificity for b-(1,6)-
glucan cell wall constituents of commensal yeast and filamen-
tous fungi (Hoogeboom et al., 2013). CLL cells have an aberrant
phenotype that includes IgM downregulation, reduced respon-
siveness to BCR ligands, reduced expression levels of CD21,
above-baseline intracellular Ca2+, and activation of BCR
pathway kinases, as well as negative feedback regulation,
including SHP-1 activation (Caligaris-Cappio, 1996; Du¨hren-
von Minden et al., 2012; Tibaldi et al., 2011). In fact, CLL cells
have been likened to anergic autoreactive B cells (Caligaris-
Cappio, 1996) that are somehow aberrantly rescued by the
tumor microenvironment (Muzio et al., 2008; Stevenson et al.,
2011).
The anergic B cell subset shares these BCR-dependent
features, including high intracellular Ca2+ as well as ERK-phos-
phorylation and feedback regulation (Goodnow et al., 1988;
Yarkoni et al., 2010). Importantly, it was shown that anergic B
cells could be rescued from apoptosis by T helper (Th) cells,
allowing normal Th cell–B cell collaboration and autoantibody
production (Fulcher et al., 1996). These results raise the question
as to whether Th cells could play a similar role in CLL.
T cells, mostly of the CD4+ Th cell type but also of the
CD8+ cytotoxic T lymphocyte (CTL) type, are known to infiltrate
pseudofollicles of CLL (Pizzolo et al., 1983). We previously
showed in a mouse model that Th cells specific for a B cell
lymphoma marker, BCR V regions (idiotype [Id]), can chronically
activate B cells, resulting in the development andmaintenance of
B cell lymphomas (Zangani et al., 2007). These findings
suggested that Th cells might play a supportive role in B cell
malignancies in humans.
Here, we hypothesize that proliferation of CLL cells in patients
may be driven by cognate interactions with Th cells, duringwhich
CLL cells present antigen to antigen-specific Th cells. Such an
antigen could be derived from an extracellular source, or it could
be produced by the CLL cell itself (endogenous Ag).
To examine this hypothesis, we must resolve three central
questions: (1) Are CLL cells in the resting state able to endo-
cytose, process, and present antigen efficiently to Th cells? (2)
If so, can stimulated Th cells reciprocate and support the acti-
vation and proliferation of CLL cells? (3) If the answer to the first
two questions is yes, what antigen is involved in such a cognate
interaction?
Before turning to Th cells from CLL patients, we first investi-
gated the antigen-presenting cell (APC) function of resting CLL
cells by targeting antigen to various antigen uptake pathways.
Utilizing an antigen-specific Th cell clone (not related to CLL),
we demonstrated that resting CLL cells were able to efficiently
endocytose, process, and present complex protein antigens
on major histocompatibility complex (MHC) class II. This model
system allowed quantitative and well-controlled analysis of
cognate Th cell–CLL cell interactions. Reciprocally, the CLL cells
were receptive to help from this antigen-specific Th cell clone. In
the second part of the study, we extended these experiments to
Th cells from individual CLL patients. We generated Th cell lines
for each patient by stimulating Th cells with the patients’ own
CLL cells. We found that such patient Th cells had specificity
for endogenous CLL cell antigen, including epitopes within the
BCR. These autologous Th cells supported CLL cell activation
and proliferation in vitro as well as in vivo in the bone marrow
niche of Nod Scid gamma (NSG) mice.
RESULTS
CLL Cells Can Endocytose Complex Antigen and Are
Efficient APCs for Specific CD4+ Th Cells
If Th cell–CLL cell interactions play a role in expanding CLL cells
in patients, resting CLL cells must have the ability to efficiently
activate Th cells. Before investigating CLL cell interactions with
autologous Th cells (see below), we first studied the antigen-
presentation capacity of CLL cells by utilizing a human Th cell
clone that is specific for a nonamer peptide derived from the
constant region of mouse kappa (Ms Ck) light chains presented
on histocompatibility leukocyte antigen (HLA)-DRB1*0401
(Schjetne et al., 2002). This Th cell clone is not related to CLL,
but it allowed functional studies of the antigen presentation of
CLL cells and antigen-dependent cognate interaction with Th
cells. In this model system, DR0401+ CLL cells (8/28 patients;
Table S1) endocytosed antigen (Ms Ck+IgG) via Ms Ck+IgG tar-
geted to cell-surface receptors in the endocytic pathway (see
Figure 1A for the experimental strategy). As for relevant targets,
we found that CLL cells expressed endocytic receptors such as
Fc receptors (CD32 and CD23) and BCRs, although the number
of BCRs present was less than 10% of that found on normal B
cells (Figures 1 and S1).
With a 90% reduction in BCR on CLL cells (Figure 1B), the
utility of the BCR for internalization of antigen may be ques-
tioned. In fact, delivery of antigen to the BCR of CLL cells
resulted in a surprisingly potent stimulation of Th cells: with
one exception (CLL110, of the eight CLL tested), APC function
was comparable to that of normal B cells (Figure 1B). CLL cells
were also efficient in uptake, processing, and presentation
when Ms Ck+IgG antigen was targeted to conventional antigen
uptake pathways (CD32 and CD23), but not to markers absenton the CLL cells, such as CD16 or inappropriate light chains (Fig-
ures 1C and S1). CLL cells lacking the DR0401 restriction
element (CLL105, CLL112, CLL113, CLL114, CLL117, CLL124,
and CLL109) were incapable of stimulating Th cells (Figures 1C
and S1). Pretreatment of CLL cells with demethylated CpG
DNA, which increases the surface levels of costimulatory and
HLA class II molecules on CLL cells (Decker et al., 2000), did
not significantly improve APC function (Figure S1). This demon-
strated a pre-existing APC efficiency of resting CLL cells. The
APC function of purified CLL cells was equivalent to that of
unpurified CLL cells from peripheral blood mononuclear cells
(PBMCs), as CLL cells accounted for >98% of the MHC class
II+ cells in the PBMCs (Figure S1). The Th cell stimulation
obtained with targeted antigen was similar or superior to that
induced by the Th cell mitogen phytohemagglutinin (data not
shown). In summary, CLL cells were found to have an intact abil-
ity to endocytose, process, and present antigen to CD4+ Th cells,
comparable to that of normal B cells.
Antigen-Specific Th Cells Induce CLL Cell Activation
Because the CLL cells were efficient antigen-dependent acti-
vators of Th cells, we turned our attention to the reciprocal acti-
vation and analyzed whether CLL cells could be stimulated by
antigen-activated Th cells (see Figure 2A for the experimental
strategy). DR0401+ CLL cells responded significantly in a Th
cell- and antigen-dependent manner by becoming activated
blasts, upregulating activation markers (CD69 and CD38),
HLA-DR and costimulatory receptors (CD86), adhesion mole-
cules (CD54), receptors for Th cell help (CD40), and receptors
for Th cell cytokines (CD25), Figures 2B–2D and S2. CLL cells
did not lose HLA-DR expression and resembled plasma blasts
(Figure 2D). CD27 and CD275 (ICOS-ligand) levels were
reduced, consistent with activation-induced shedding. Target-
ing antigen to the BCR yielded CLL cell responses similar to
those obtained with delivery via CD32 (Figures 2D and S2).
CLL cells lacking DR0401 did not activate T18 in the presence
of antigen and therefore received no help from T18 cells. Thus,
CLL cells from four DR0401-negative patients did not show in-
duction of the activation markers shown in Figures 2D and S2.
Antigen-Driven Th Cell–CLL Collaboration Can Support
Secretion of CLL-Derived Monoclonal Ig
Some CLL patients have low levels of CLL-derived monoclonal
Ig in the serum. CLL cells that collaborated with Th cells in an
antigen- and Th cell-dependent manner increased both surface
and intracellular levels of Ig (Figure 2E). Moreover, T cell-acti-
vated CLL cells secreted IgM, detected as IgM with the appro-
priate L chain (either k or l). We found very little IgM with the
inappropriate L chain, demonstrating a negligible contribution
of normal B cells (Figure 2F). The levels of secretion varied mark-
edly between the CLL cells (20- to 40-fold), indicating an intrinsic
variation in the ability of CLL cells to secrete Ig.
Th Cells Induce CLL Cell Proliferation in an Antigen- and
Contact-Dependent Manner
In addition to the activation described above, CLL cells prolifer-
ated when they collaborated with Th cells in an antigen- and cell-
contact-dependent manner, a response that could be inhibitedCell Reports 4, 566–577, August 15, 2013 ª2013 The Authors 567
Figure 1. Analysis of the Efficiency of CLL Cells to Endocytose, Process, and Present Antigen to Th Cells
(A) CLL cells were tested for their ability to internalize, process, and present complex protein antigen in the form of mouse anti-human mAbs. Mouse antibodies
expressing k L chains all harbor a peptide determinant in the Ck of the L chain. After processing, this Ck peptide can be presented on HLA DRb*0401 and
recognized by the Ck-peptide/DR0401-specific T18 Th cell clone. Left: Testing mouse anti-human k (Ms k+IgG anti-Hu) versus mouse anti-human l (Ms k+IgG
anti-Hu l), corresponding to experiments in B). Right: Testing mouse anti-human CD32 (Ms k+IgG anti-Hu CD32), corresponding to experiments in C).
(B and C) Proliferation of MsCk/DR0401-specific T18 cells (3HTdR incorporation) in response to presentation of Ms k+Ig by DR0401+-CLL cells.
(B) Top: numbers of BCRs (detected by L-chain stain) on normal B cells compared with CLL cells. Bottom: CLL cells present antigen endocytosed via BCRs (Ms
k+IgG anti-Hu k or Ms k+IgG anti-Hu l) with efficiency comparable to that of normal B cells. The L chain isotype (k or l) expressed on patient CLL cells is indicated
by the black symbol (boxed symbols in legend table); nonexpressed L chain isotypes are gray. Controls (CLL alone, Th cells alone, Th cells alone with antigens,
and CLL cells with Th cells but no antigen) are indicated by overlapping open circles.
(C) Top: numbers of CD32molecules on normal B cells versus CLL cells. Bottom left: Th cell proliferation in response to antigen (Ms k+IgG anti-Hu CD32) targeted
to CD32 on DR0401+ CLL cells compared with control (CLL109, DR0401). Bottom right: Th cell proliferation in response to antigen (Ms k+IgG anti-Hu CD32)
delivered via CD32 on DR0401+ CLL cells (open symbols) and normal DR0401+ B cells (filled symbols). Error bars: SD.
See also Figure S1 and Table S1.by anti-CD40L (Figures 3 and S3). Blastoid CLL cells underwent
DNA replication (bromodeoxyuridine [BrdU] incorporation) in
response to Th cells and antigen (Figure 3A). However, in about
half of the patients, in spite of activation and blastogenesis, the
proliferation was minor. In these patients, CLL cells only prolifer-
ated in a Th cell- and antigen-dependentmanner when theywere
provided with exogenous interleukin-2 (IL-2), TLR9 ligands
(CpG2006), or both (Figure S3). Such in vitro cofactor-dependent
CLL cells nevertheless proliferated in response to help in vivo
(see below).
Polyclonal Patient Th Cells Can Induce the Activation
and Proliferation of CLL Cells
The CLL responses described above were obtained with a single
Th cell clone. To test whether such CLL cell responses were a
general feature of interactions with activated Th cells, we gener-568 Cell Reports 4, 566–577, August 15, 2013 ª2013 The Authorsated alloreactive T cell lines from patients and healthy vol-
unteers. Both patient and control polyclonal alloreactive T cells
supported activation and proliferation of CLL cells in a manner
similar to that described above (Figure S4). In these allo-driven
T cell–CLL cell collaboration assays, we also included CLL
cells from six DR0401 patients in the analysis, and found that
these CLL cells were activated similarly to CLL cells from the
eight DR0401+ patients tested as described above. These exper-
iments demonstrated that Th cells from patients were not func-
tionally impaired and could support antigen-dependent CLL
activation.
Autologous CLL-Specific Th Cell Lines Can Support CLL
Cell Activation
The above results suggested that immune responses involving
CLL cells, Th cells, and either exogenous antigens or
Figure 2. Analysis of CLL Cell Activation and Antigen-Driven CLL
Cell–Th Cell Collaboration
(A–F) Analysis of the outcome of the antigen-dependent Th cell activation of
CLL cells. Assays as shown in Figure 1 were performed on CLL cells with the
appropriate HLA-DR0401. CLL cells were analyzed for expression of surface
markers (B–D) or cell size and production of monoclonal IgM (E and F).
(B–F) PBMCs from patients were incubated in the presence or absence of T18
and antigen (Ms k+IgG anti-HuCD32 or Ms k+IgG anti-BCR [a mixture of both
Ms k+IgG anti-Hu k and Ms k+IgG anti-l]) for 96 hr.
(B) Contour plot of DR0401+ CLL106 CLL cells (CD5+19+ gate) showing CD86
versus CD54 surface expression in the presence or absence of T18 and
antigen.endogenous CLL antigens could support CLL cell growth in
pseudofollicles. We therefore turned our attention to the Th cells
in patients (see Figure 4A for the experimental strategy). In fact,
proliferating Th cells could be observed directly in unfractionated
PBMCs, but not in the absence of CLL cells (Figures 4B and 4C).
These Th cells were derived from CD45RO+ (memory) Th cells
(Figure 4C). The results demonstrated that patients had a subset
of Th cells that were stimulated directly by the patients’ own CLL
cells. Th cells were restimulated every 10 days by autologous
CLL cells to generate CLL-specific Th cell lines (Figures 4A
and 4D). After three 10-day stimulation cycles, the CLL-specific
Th cell lines proliferated in response to either autologous CLL
cells or autologous CLL cell lysate presented by APCs from
HLA class II matched donors (Figures 4A, 4E, and 4F). Moreover,
suchCLL-specific Th cells stimulated HLA class II-restrictedCLL
cell activation and proliferation in a manner equivalent to that
described above, including dependency upon the CD40/
CD154 pathway (Figure 4G). Further, the CLL-specific Th cells
stimulated the activation of CLL cells at a level comparable to
that seen with the T18 Th cell clone or allo-specific Th cells.
CLL cells upregulated the activation markers BCR, CD54,
CD25, CD40, CD38, and HLA-DR, but not CD138 (Figures 4H,
4I, S3, and S4). Finally, we tested Th cells for responses toward
epitopes within the CLLBCR. HLA-matched donor cells present-
ing monoclonal antibody (mAb) derived from CLL hybridomas
activated autologous Th cells, demonstrating a significantly
increased Th cell specificity for this endogenous CLL antigen
(Figure 4J). We therefore conclude that effector Th cells specific
for endogenous CLL antigens can exist in CLL patients and that
they can support CLL cell growth and differentiation.
Autologous CLL-Specific Th Cell Lines Can Support CLL
Cell Activation and Proliferation In Vivo
It was previously described that autologous Th cells can support
CLL cells in NSG mice, presumably through activation of
expanding xenoreactive Th cells with accompanying bystander
activation of CLL cells. In such mice, CLL cells do not expand
without Th cells (Bagnara et al., 2011). We conditioned mice
with busulfan (see Experimental Procedures) before injecting
(1) patient PBMCs or (2) PBMCs and CLL-specific Th cells (Fig-
ure 5A). In the latter group, the proliferation of both CLL cells and
Th cells was dramatically and significantly increased in the bone(C) Gated CD5+19+ CLL103 cells (DR0401+) in histograms showing surface
expression of CD25 and CD38 versus isotypic control (gray).
(D) Surface markers on CLL cells of DR0401+ patients stimulated as listed on
the y axis. +BCR or +CD32 indicates that Ms k+IgG antigen was delivered to
the BCR or CD32. Staining intensity relative to background is shown on the
x axis (see Experimental Procedures). Note that in one graph, the mean for-
ward scatter (FSC*) is plotted. See also Figure S2 for examples of the flow-
cytometry plots used for data generation.
(E) IgM staining of permeabilized cells (extracellular + intracellular IgM
expression) versus FSC in DR0401+ CLL106 cells cocultured with T18 in the
presence or absence of antigen (Ms k+anti-HuCD32).
(F) Secretion of IgM by activated CLL cells. Purified CD5+ CLL cells were
preincubated with antigen (see Experimental Procedures) and mixed with T18
cells as indicated. Secreted IgMl and IgMk were measured by ELISA. The L
chain expression (k/l) of the various CLL cells is indicated in parentheses. n =
4; error bars: SD is shown.
See also Table S1.
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Figure 3. Analysis of Reciprocal Th Cell
Stimulation of CLL Cells
(A and B) Activation of CLL cells in response to
collaboration with antigen-specific T18 cells.
(A) IgM (intra- and extracellular expression) versus
BrdU staining on CD5+CD19+ gated CLL106 cells
from Transwells (see Experimental Procedures) as
indicated in the presence or absence of antigen
(Ms k+IgG anti-Hu l or Ms k+IgG anti-CD32).
(B) Ms k+IgG anti-CD32 Ag/Th-cell-dependent
CLL cell activation in the presence of anti-CD40L
or isotype. Expression of CD38 versus CD69 is
shown.
See also Figure S3 and Table S1.marrow, demonstrating that autologous pairs of CLL cells and
CLL-specific Th cells could support the proliferation of each
other in this niche (Figures 5B and 5C). It is notable that CLL cells
from the patient shown in Figure 5 belonged to the group of
patients whose Th cells supported the activation and blastogen-
esis of CLL cells, but CLL cells required cofactors for marked
proliferation in vitro (Figure S3). Because cofactors were not pro-
vided in these in vivo experiments, the results suggest that stro-
mal factors help support the T cell–CLL cell expansion in vivo.
Autologous CLL-Specific Th Cell Lines Have a Th1-Like
Phenotype
Activated autologous Th cells secreted interferon g (IFN-g; Fig-
ure 6A; data not shown) and had surface markers indicating a
Th1-like phenotype. The Th cells expressed the IFN-g-associ-
ated transcription factor T-Bet and were CXCR3+, CCR5/+,
CCR6, CRTh2 (CD294), CXCR5, ICOS, IL-21, PD-
1(CD279)/low, and Bcl-6 (data not shown). Reciprocally, we
confirmed that CLL cells express the T-Bet transcription factor
(Figure 6B), as described previously in analyses of CLL in pseu-
dofollicles (Dorfman et al., 2004).
CLL Cells that Collaborate with Antigen-Specific Th
Cells Undergo Marked Changes in Gene Expression
To further study the CLL cell–Th cell collaboration and CLL cell
activation, we utilized a well-defined model system and T18
cell clone. The gene expression profiles of purified CLL cells
from T-B collaboration assays (antigen: Ms Ck+IgG anti-l/k)
were analyzed (Figure 7). The CLL cells had undergone signifi-570 Cell Reports 4, 566–577, August 15, 2013 ª2013 The Authorscant changes in the expression of 1,604
genes (730 upregulated and 874 downre-
gulated; Figure 7), including significant
upregulation of mitosis-related genes
(Table S2). Gene set enrichment analysis
(GSEA; http://www.broadinstitute.org/
gsea/) indicated significant similarity to
cancer-related GSEA modules, including
gene sets that are expressed in large
cell lymphomas but are repressed in
CLL cells (Table S3). Similar results were
obtained using the Global Cancer Map
tool (Broad Institute) and Oncomine anal-
ysis tool (Figure 7E; Table S4). Further,genes involved in negative regulation of apoptosis were signifi-
cantly upregulated, whereas apoptosis-inducing genes were
downregulated (Tables S5 and S6). To reveal potential signaling
pathways responsible for the altered gene expression, we further
tested the upregulated genes for potential transcription factor
binding sites (Table S7) and found a significant association
with transcription factors such as members of the NF-kB1
pathway. The gene expression profiles of CLL cells within pseu-
dofollicles in lymph nodes were described in a recent study (Her-
ishanu et al., 2011), and we found that 52 of the upregulated
genes described herein overlap with the 133 overexpressed
lymph node genes reported in that study (Herishanu et al.,
2011; Table S8).
DISCUSSION
Previous studies have reported a high frequency of Th cells in
CLL pseudofollicles (Pizzolo et al., 1983; Ghia et al., 2002; Patten
et al., 2008). In this work, using a model system and a Th cell
clone not related to CLL, we found that CLL cells could efficiently
present complex protein antigen to Th cells, provided that anti-
gen was delivered to the conventional antigen uptake pathways,
including the BCR as well as Fc receptors. Subsequent to anti-
gen presentation by resting CLL cells, Th cells reciprocally
induced CLL cell proliferation and differentiation, including upre-
gulation of costimulatory receptors and activation markers on
CLL cells, blastogenesis, secretion of Ig, and altered gene
expression profile, but not loss of HLA-DR expression. Turning
to patients and their Th cells, we found that the CLL patients
harbored Th cells that were stimulated by endogenous antigens
presented by CLL cells, and that a fraction of such Th cells
were specific for CLL cell antibody. These CLL-specific Th cells
in CLL patients had a Th1-like phenotype and could support
significantly increased CLL proliferation in the bone marrow of
NSG mice. Taken together, the results suggest that CLL is a
disease driven by immune responses via a process in which Th
cells engage CLL cells in response to exogenous antigen (which
may be efficiently internalized by the BCR and other uptake
pathways), or Th cells respond to endogenous CLL cell antigen
presented on the CLL cells’ own HLA class II molecules, as
demonstrated here.
With regard to the mechanism for antigen-driven Th cell–CLL
cell collaboration, the central facets are similar to those of normal
Th cell–B cell collaboration, i.e., dependency upon (1) presenta-
tion of antigen on HLA class II, and (2) cell-cell contact, including
the CD40/CD40L pathway (Grewal and Flavell, 1998). Some
studies have described CLL cells as poor APCs in mixed leuko-
cyte reactions prior to any activation (Halper et al., 1979; Ran-
heim and Kipps, 1993), whereas others demonstrated efficient
antigen-dependent stimulation (Yasukawa et al., 1988; Hall
et al., 2005). Here, we found that CLL cells are equally efficient
as normal B cells in presenting antigen to memory Th cells. After
cognate Th cell activation by the CLL cells, Th cells helped CLL
cells in a contact- and CD40-dependent manner. As a result,
the CLL cells upregulated costimulatory and adhesion mole-
cules, as well as HLA-DR, that could augment antigen presenta-
tion. These findings extend previous studies that demonstrated
a noncognate, bystander activation of CLL cells in vitro and
in vivo (Tretter et al., 1998; Patten et al., 2005; Bagnara et al.,
2011).
Other aspects of the antigen-driven Th cell–CLL cell interac-
tion did not conform to the norm: (1) CLL cells became activated,
proliferating Ig-secreting blasts, but did not downregulate HLA/
costimulatory molecules or express the plasma cell marker
CD138. Interestingly, it has been shown that polyclonally acti-
vated Th cells induce blastogenesis but do not downregulate
the aberrantly expressed survival factor lymphocyte enhancer
binding factor 1 (LEF-1), in contrast to CpG/cytokine-stimulated
blasts that have reduced LEF-1, allowing apoptosis (Gutierrez
et al., 2011). (2) CLL cells did not require additional BCR signals
to undergo this activation, as antigen delivered to non-BCR
endocytosis receptors was sufficient (see discussion below).
(3) CLL cells could present endogenously derived antigen to Th
cells, and such Th cells were readily detectable in patients. In
line with the third point, it was previously shown that patients
may have Th cells specific for antigens such as Id, but the signif-
icance and function of such Th cells have not been determined
(Rezvany et al., 2000).
It has been speculated that CLL cells represent the malignant
counterparts of anergic B cells, a subset destined to apoptose
due to chronic BCR stimulation (Caligaris-Cappio, 1996; see
Introduction). Concerning the role of BCR ligation in experi-
ments such as those conducted here, a level of BCR signaling
may already be ongoing in CLL cells, indicating an ‘‘anergic
signaling phenotype’’ (Chiorazzi and Efremov, 2013; Stevenson
et al., 2011), although it has been suggested that this signaling
may be balanced by the tuning and establishment of a contin-uum of functional anergy as seen in mice studies (Zikherman
et al., 2012). In any case, additional ligation by fluid-phase
BCR mAbs produced little change in gene expression. By
contrast, after antigen-dependent activation by Th cells, the
CLL cells dramatically changed gene expression and expressed
52 of 133 of the genes found to be upregulated in CLL cells
in lymph nodes of patients (Herishanu et al., 2011). In terms
of signaling, CD40 ligation rapidly activates the canonical
NF-kB1 pathway through members of TNFR-associated factor
(TRAF) family of cytoplasmic proteins, causing RelA-dependent
gene expression, in addition to slower noncanonical NF-kB2
activation (RelB) (Bishop et al., 2007). However, the BCR and
CD40 share multiple components, such as the protein tyrosine
kinases Syk, Lyn, Btk, and Akt, as well as the PI-3 kinase and
phospholipase Cg2 (Faris et al., 1994; Ren et al., 1994; Ying
et al., 2011; Bishop et al., 2007). Hence, in line with the above
discussion about anergic B cells, we suggest that the BCR
pathway (constitutively triggered) and CD40 pathway (CD40L
on Th cells) converge (Ying et al., 2011) to allow CLL cell
activation.
As regards Th cells, important previous findings have special
relevance to the current work. First, mitogenic stimulation of
CLL cells has been described to have a Th cell component,
because the presence of T cells augments the activation of
CLL cells (Robe`rt, 1979). Second, allogeneic Th cell help was
sufficient for generation of blasts secreting IgM (Fu et al.,
1979). Third, Th cells were found juxtaposed to activated prolif-
erating CLL blasts in pseudofollicles (Ghia et al., 2002; Patten
et al., 2008). Fourth, such Th cells expressed CD40L (CD154),
indicating recent activation (Ghia et al., 2002) as well as a poten-
tial to stimulate CLL cells via CD40. The crucial outstanding
question is, why and how are such Th cells activated, and
what antigen do they recognize? There are three distinct but
not mutually exclusive possibilities: (1) Th cells could be specific
for antigens derived from a hitherto unrecognized pathogen, or
respond to yeast or fungal antigens internalized by anti-b-(1,6)-
glucan expressing CLL cells (Hoogeboom et al., 2013); (2) Th
cells could be specific for autoantigens presented by the CLL
cell (Hall et al., 2005); and (3) Th cells could be specific for secre-
tory pathway autoantigens (Weiss and Bogen, 1991; Rezvany
et al., 2000) that are endogenously expressed in the CLL. In
the current work, we find that Th cells are specific for proteins
in CLL lysates, and that some of the Th cells in such polyclonal
lines are specific for the CLL mAb.
We found that the autologous CLL-specific Th cells were
IFN-g secreting Th1-like cells, as was previously reported (Gitel-
son et al., 2003). Moreover, similar results were very recently
found in preliminary studies of Th cells from lymph nodes with
CLL cell involvement (S.B., A.P.R., A.O., K.M.T., G.E.T., B.B.,
and L.A.M., unpublished data). How does this finding compare
towhat is known about themicroenvironment in pseudofollicles?
First, CLL cells secrete CCL3 and CCL4 chemokines that attract
Th1 cells (Burger et al., 2009). Second, CLL patients have
increased IFN-g in sera, and IFN-g can inhibit the apoptosis of
CLL cells (Buschle et al., 1993). Third, CLL cells are positive for
the IFN-g-associated transcription factor T-Bet (Dorfman et al.,
2004), as also confirmed herein. Thus, the results suggest that
IFN-g may play an important role in the survival of CLL cells.Cell Reports 4, 566–577, August 15, 2013 ª2013 The Authors 571
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Figure 5. Analysis of Th Cell Collaboration
with CLL Cells In Vivo
(A) Autologous CLL-specific Th cells were gener-
ated. PBMC CLL cells were injected into NSG
mice alone or together with autologous CLL-spe-
cific Th.
(B) Stimulation of CLL107 cells by TCL107 in the
bone marrow (BM) of NSG mice. k L chain
expression versus in vivo BrdU incorporation of
gated CD19+ CLL cells is shown (quadrants: mean
[SD]; n = 4, p < 0.0004). Right: A priori expression
of k L chains, and control (background) anti-BrdU
staining of CLL cells.
(C) Stimulation of TCL107 by CLL107 cells in the
BM of NSG mice. Proliferation (BrdU) versus cell
size (FSC) of gated CD4+ cells is shown. Left: mice
receiving TCL107; right: mice receiving only
PBMC, PBMC CD4+ Th cells are shown (quad-
rants: mean (SD); n = 4; BrdU+ cells, p < 0.0001).
See also Table S1.CLL-specific Th cells could be readily demonstrated in
patients and responded with proliferation and cytokine secre-
tion to the presentation of endogenous CLL cell antigen. Pre-
viously, T cells have been thought to be functionally deficient
(Go¨rgu¨n et al., 2005). Even so, a relatively high-frequency Th
cell repertoire has been demonstrated against CLL cells or
defined endogenous antigen (Rezvany et al., 2000; Kokhaei
et al., 2007; Gitelson et al., 2003). Moreover, CLL cells have
been implicated in the stimulation of autoreactive Th cells in
CLL patients suffering from autoimmune hemolytic anemia,
suggesting that CLL cells play a role in breaking the tolerance
of Th cells in such patients (Hall et al., 2005). As concernsFigure 4. Analysis of Interaction between Autologous CLL-Specific Th
(A) Outline of the experimental strategy. PBMCswere investigated for Th cells und
cells were tested for response toward autologous CLL cells (C). Th cells were st
tested for responsiveness toward CLL cells and HLA-matched donor APCs pres
autologous CLL cells (G–I). Th cells were tested for responsiveness toward CLL-
(B) Carboxyfluorescein succinimidyl ester (CFSE)-labeled PBMCs frompatients C
without supplements as indicated. Left: CD4 versus CFSE contour plot. Box a
CD4+CD19 cells. The percentage of CFSE-decayed cells (marker) is indicated.
(C) BrdU incorporation of sorted CD4+CD45RO+ CD45RA T cells from the bloo
(D) Establishment of CLL-specific Th cell lines (TCL). CD4+ Th cells were purified fro
2 in mediumwith autologous serum as the protein supplement. After 10-day cycle
(E and F) Responses of gated CD4+CD19 Th cells.
(E) Proliferation of TCL107 cells (Th cells alone [left] or in the presence of autolog
(F) TCL107 is specific for a CLL107 antigen. TCL107 was cultured with or without P
presence of lysate of freeze-thawed CLL107 cells as indicated.
(G–I) Responses of gated CD5+CD19+ CLL cells are shown.
(G) Stimulation of CLL107 by TCL107 is inhibited by HLA class II or CD40L (CD15
CpG, IL-2, and TCL107 in the presence of anti-pan HLA class II or the appropriate
Right: CLL107 cells were cultured in the presence of TCL107 and anti-CD40L or
each of these two conditions. Gray, isotypic control for CD38 FACS staining.
(H) Stimulation of CLL113 CLL cells by autologous CLL113-specific TCL113 Th ce
cells versus CLL cells alone).
(I) Analysis of CLL105 CLL cell response (CD38 upregulation) to the autologous CL
Experimental Procedures).
(J) Stimulation of TCL106 by HLA-matched donor APCs presenting purified IgM fr
the absence or presence of CLL106 mAb (as indicated). FSC versus BrdU incorp
CLL106 mAb in six separate experiments. Error bars indicate SD.
See also Figure S4 and Table S1.CD8+ T cells, patients have CTLs of low frequency that
respond to CLL idiotypic peptide (Trojan et al., 2000). Howev-
er, there is increasing evidence of exhaustion in an expanded
subset of CTLs that may have been chronically stimulated by
CLL cells directed toward an unknown antigen (Riches et al.,
2013).
The current work extends previous results that suggested that
Th cells may play a role in the pathogenesis and expansion of
CLL cells (Ghia et al., 2002; Patten et al., 2005, 2008; Tretter
et al., 1998; Bagnara et al., 2011). Our findings that (1) CLL cells
are functionally normal APCs, (2) patients harbor a subset of
CLL-specific Th cells, and (3) these Th cells support CLL cellCells and CLL Cells
ergoing cell divisions ex vivo in the presence of CLL cells (B). Sortedmemory Th
imulated by CLL cells to make CLL-specific Th cell lines (D). Th cell lines were
enting CLL cell lysates (F). Th cell lines were tested for their ability to stimulate
derived IgM presented by HLA-matched donor APC (J).
LL113 andCLL107were cultured for 5 and 7 days, respectively, inmedia with or
nd arrows: CFSELow proliferating Th cells. Right: CFSE expression of gated
d of patient CLL113 in response to autologous CLL cells (left) or alone (right).
m patient PBMCs and stimulated by autologousCLL cells in the presence of IL-
s, the cells were counted and restimulated. Relative Th cell numbers are shown.
ous CLL107 [right]).
BMCs from an HLA-DR, DQ, and DPmatched healthy donor in the absence or
4) mAb. Left: CD19+ CLL107 cells were purified and cultured in the presence of
isotype control. FSC versus BrdU incorporation in CLL cells on day 4 is shown.
an appropriate isotype control. The CD38 expression of CLL cells is shown for
lls for 72 hr. Fold change of markers on gated CLL cells (Th-cell-activated CLL
L105-specific Th cell line TCL105 in the presence of cytokines or CpG2006 (see
om CLL106 hybridoma (CLL106 mAb). TCL106 was cultured with donor APC in
oration is shown. Right bar graph: TCL106 responsiveness to presentation of
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Figure 6. Analysis of IFN-gSecretion by AutologousCLL-Specific Th
Cells and T-Bet Expression in CLL Cells
(A) IFN-g secretion by activated autologous CLL-specific T cell lines (IFN-g
versus FSC).
(B) Expression of T-Bet in CLL cells (T-Bet [line] versus isotype [filled histo-
gram]).
See also Table S1.activation and expansion suggest that Th cells are important
drivers in this disease. Further work is required to define the
fine specificity of the CLL-specific Th cell subset in patients
and to extend such analyses to the microenvironment of the
lymph node.EXPERIMENTAL PROCEDURES
Patient Material and Normal Controls
Patients who had been diagnosed with CLL (see Table S1) were recruited at
the hematological outpatient clinic at Oslo University Hospital, Rikshospitalet,
Norway, after they provided informed consent. The regional ethics committee
approved the project.Th Cell and CLL Cell Isolation
CD4+ Th cells were purified from patient or control PBMCs using the Dyna-
beads FlowComp Human CD4 kit (Dynal; Invitrogen) according to the product
manual. CLL cells were positively selected usingMACS beads (Miltenyi Biotec)
by selection via rituximab (anti-CD20, devoid of Ms Ck-antigen), anti-CD19, or
anti-CD5 as indicated. In the antibody secretion assay (Figure 2F), CLL cells
were positively selected (and concomitantly loaded with antigen) with Ms
Ck+ biotinylated CD5+ mAb/streptavidin-MACS beads.Culture of CD4+ Th Cells and Generation of Th Cell Lines
Autologous CLL-specific Th cells were stimulated by autologous irradiated
CLL cells in culture media supplemented by autologous serum, and thereafter
using pooled human serum from healthy donors. The Th cell lines and the T18
clone were stimulated in 10-day cycles by irradiated APCs, with provision of
20 U/ml recombinant human IL-2 (rhIL-2; Roche). Alloreactive CD4+ Th cell
lines were generated by stimulating purified CD4+ cells with 20 Gy irradiated
mixed allogenic PBMCs from more than five CLL patients (see Extended
Experimental Procedures for details).574 Cell Reports 4, 566–577, August 15, 2013 ª2013 The AuthorsTh Cell Proliferation Assays and Th Cell–CLL Cell Collaboration
Assays
Th cells (5 3 104/well) were tested for proliferation (3H-thymidine incorpora-
tion) in 96-well plates in response to irradiated CLL cells or PMBCs (2 3
105/well) and antigen as indicated. Alternatively, cocultured cells were tested
for BrdU incorporation (see Extended Experimental Procedures for details).
CpG ODN2006 (1–2 mg/ml; Invivogen) and rhIL-2 (Roche) were included
in some assays as indicated. Pathway inhibition was performed with HLA
DR, DP, or DQ mAb (Tu39; Becton Dickinson), or CD154 mAb (24-31;
eBioscience).Antigens in T18 Assays
Antigen was delivered to the processing pathway of CLL cells utilizing Ms Ck+
mAbs targeting the following: Hu l L chain (4C2), Hu k L chain (A8B5) (both L
chain mAbs with the same isotype [IgG1]), and IgM (1030) from Diatec; CD16
(CB16) and CD23 (EBVCS2) from eBioscience; and CD32 (3D3) and CD81
(VB070) from Becton Dickinson. In the assays shown in Figures 1A and 1B,
cells from normal DR0401+ donors N1 and N2 received a mixture of Ms
k+IgG anti-Hu l and Ms k+IgG anti-Hu k to allow uptake and presentation by
both l- and k-positive B cells. In the assays shown in Figure 2F, CD5+CLL cells
were purified with MACS utilizing Ms k+anti-HuCD5 mAb. In these assays,
sorted, antigen-loaded CLL cells (Ms k+anti-HuCD5 plus additional Ms
k+anti-HuCD23) were incubated with T18 cells.Surface Antigen Quantification
Quantification of surface antigen was performed using mAbs in the T18 assays
described above and the bead-based Cellquant Calibrator kit (BioCytex)
according to the manufacturer’s guidelines.Fluorescence-Activated Cell Sorting Analysis
Fluorochrome-labeled mAbs with the indicated specificities or isotype con-
trols were used for fluorescence-activated cell sorting (FACS) analysis of sur-
face expression and proliferation on the indicated days. See the Extended
Experimental Procedures for an extensive list of mAbs. In Figures 2 and 4,
the changes in staining intensity are shown as the ratio of signal with the
mAb specific for the marker compared with the isotype control (ratio =
MFImarker/MFIisotype).In Vivo Experiments
Mice experiments were approved by the National Committee for Animal
Experiments (Oslo, Norway). NSGmice (The Jackson Laboratory) were condi-
tioned with busulfan (Busilvex; Pierre Fabre Pharma) and injected i.v. with
PBMCs or PBMCs and CLL-specific Th cells. Mice were analyzed on day
42; see the Extended Experimental Procedures for details.Microarray Experiments
CLL cells with or without 2 mg/ml of mouse k+ k and l IgG antibodies were incu-
bated with T18 Th cells. On day 3, CLL cells were purified (see Extended
Experimental Procedures). The purity of CD19+CD4 cells for gene expression
profiling as assessed by flow cytometry was 93%–99%, median 98%. CD4+
cell contamination was low (0.00%–0.6%, median 0.05%). For details on
RNA purification, data acquisition, and analysis see the Extended Experi-
mental Procedures.Statistics
One-way ANOVAwith the Bonferroni multiple-comparisons test and Student’s
t test was performed as indicated.ACCESSION NUMBERS
The microarray data series has been deposited in the Gene Expression
Omnibus under accession number GSE48268 (see http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE48268).
Figure 7. Analysis of Gene-Expression Profiles of CLL Cells Activated by T18 Cells and Antigen as Compared with Controls
(A–E) CLL cells were cultured with or without the T18 Th cell clone for 3 days in the presence or absence of Ms k+IgG anti-BCR.
(A) Unsupervised hierarchical clustering (hierarchical entity tree, Euclidean, centroid) of significantly changed gene expression after one-way ANOVA (Benjamini-
Hochberg, asymptotic p value computation, p < 0.05) comparing each of the two control groups (CLL + Th; CLL + anti-BCR) with the activated group (CLL + Th +
anti-BCR). The hierarchical entity tree presents 280 probe-defined entities that represented 244 unique Entrez gene Id and Hugo terms.
(B) Unsupervised hierarchical clustering (Euclidean, centroid) of significantly different gene expression after unpaired t test (Benjamini-Hochberg corrected,
asymptotic p value computation, p < 0.05) comparing controls with the test group, i.e., Th cell–CLL cell collaboration (CLL + Th + anti-BCR). The hierarchical entity
tree represents 1,956 probe-defined entities, 1,604 of which were unique Entrez gene Id and Hugo terms.
(C) Profile plot of data from (B) after unpaired t test (Benjamini-Hochberg, p < 0.05), including only genes with >2-fold change.
(D) Left: Profile plot as in (C), all entities, averaged data (controls versus CLL + Th + anti-BCR stimulated cells). Right: GO-termmitotic cell cycle from data as in (B)
(unpaired t test, Benjamini-Hochberg, p < 0.05).
(E) Comparison of upregulated genes in Th cell/antigen-activated CLL with expression in the Global Cancer Map (Broad Institute; 686 of 730 genes were
recognized by the application). Red, expressed; blue, repressed (gene expression profiles from the Global Cancer Map as published in Ramaswamy et al., 2001).
See also Tables S1, S2, S3, S4, S5, S6, S7, and S8.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and eight tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.07.011.
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